Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Caitlin V. M. L., Treyer, Valerie, Schibli, Roger, Mu, Linjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911942/
https://www.ncbi.nlm.nih.gov/pubmed/33573211
http://dx.doi.org/10.3390/ph14020110
_version_ 1783656460432965632
author Jie, Caitlin V. M. L.
Treyer, Valerie
Schibli, Roger
Mu, Linjing
author_facet Jie, Caitlin V. M. L.
Treyer, Valerie
Schibli, Roger
Mu, Linjing
author_sort Jie, Caitlin V. M. L.
collection PubMed
description Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.
format Online
Article
Text
id pubmed-7911942
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79119422021-02-28 Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease Jie, Caitlin V. M. L. Treyer, Valerie Schibli, Roger Mu, Linjing Pharmaceuticals (Basel) Review Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic. MDPI 2021-01-30 /pmc/articles/PMC7911942/ /pubmed/33573211 http://dx.doi.org/10.3390/ph14020110 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jie, Caitlin V. M. L.
Treyer, Valerie
Schibli, Roger
Mu, Linjing
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title_full Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title_fullStr Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title_full_unstemmed Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title_short Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
title_sort tauvid™: the first fda-approved pet tracer for imaging tau pathology in alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911942/
https://www.ncbi.nlm.nih.gov/pubmed/33573211
http://dx.doi.org/10.3390/ph14020110
work_keys_str_mv AT jiecaitlinvml tauvidthefirstfdaapprovedpettracerforimagingtaupathologyinalzheimersdisease
AT treyervalerie tauvidthefirstfdaapprovedpettracerforimagingtaupathologyinalzheimersdisease
AT schibliroger tauvidthefirstfdaapprovedpettracerforimagingtaupathologyinalzheimersdisease
AT mulinjing tauvidthefirstfdaapprovedpettracerforimagingtaupathologyinalzheimersdisease

Ejemplares similares